The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 2 August 2005, www.theannals.com, DOI 10.1345/aph.1G025.
 The Annals of Pharmacotherapy: Vol. 39, No. 9, pp. 1517-1521. DOI 10.1345/aph.1G025
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christy, N. A
Right arrow Articles by Cross, L B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christy, N. A
Right arrow Articles by Cross, L B.

DRUG INFORMATION ROUNDS

Spironolactone for Hirsutism in Polycystic Ovary Syndrome

Natalie A Christy, PharmD

Primary Care Specialty Resident, College of Pharmacy, University of Tennessee, University of Tennessee Family Practice Center, Memphis, TN

Andrea S Franks, PharmD BCPS

Assistant Professor, Departments of Pharmacy and Family Medicine, Colleges of Pharmacy and Medicine, University of Tennessee Health Science Center, Memphis

L Brian Cross, PharmD CDE

Assistant Professor, Departments of Pharmacy and Family Medicine, Colleges of Pharmacy and Medicine, University of Tennessee Health Science Center, Memphis

Reprints: Dr. Christy, University of Tennessee Family Practice Center, 1301 Primacy Pkwy., Memphis, TN 38119-0213, fax 901/448-0404, nchristy{at}utmem.edu

OBJECTIVE: To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone.

DATA SOURCES: Studies and reports were located in MEDLINE (1966–January 2005), EMBASE, and International Pharmaceutical Abstracts through the second week of January 2005.

DATA SYNTHESIS: Hirsutism is a common clinical problem and is often associated with PCOS. Research has been performed to assess the efficacy of spironolactone therapy in patients with hirsute characteristics. Five studies that evaluated the effectiveness of spironolactone for hirsutism in PCOS were identified and reviewed.

CONCLUSIONS: The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results. The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.

Key Words: hirsutism, polycystic ovary syndrome, spironolactone

Published Online, August 2, 2005. www.theannals.com, DOI 10.1345/aph.1G025




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.